Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Operating Leases (2019 - 2025)

Corcept Therapeutics' Operating Leases history spans 6 years, with the latest figure at $6.4 million for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $6.4 million; the TTM value through Sep 2025 reached $6.4 million, changed N/A, while the annual FY2024 figure was $6.1 million, N/A changed from the prior year.
  • Operating Leases for Q3 2025 was $6.4 million at Corcept Therapeutics, up from $5.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.4 million in Q3 2025 and bottomed at $225000.0 in Q3 2023.
  • The 4-year median for Operating Leases is $2.5 million (2022), against an average of $3.2 million.
  • The largest annual shift saw Operating Leases tumbled 86.88% in 2023 before it skyrocketed 1793.94% in 2024.
  • A 4-year view of Operating Leases shows it stood at $1.7 million in 2022, then tumbled by 86.82% to $225000.0 in 2023, then soared by 2614.22% to $6.1 million in 2024, then grew by 4.11% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Operating Leases are $6.4 million (Q3 2025), $5.9 million (Q1 2025), and $6.1 million (Q4 2024).